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1. Introduction
   Oral rout of administration is the most convenient and 
widely used method of drug administration, and the 
development of stomach specific oral controlled-release 
drug delivery systems is a challenging job due to the 
variation of pH in different segments of the gastrointestinal 
tract, the fluctuation in gastric emptying time and the 
difficulty of localizing an oral delivery system in a selected 
region of the gastrointestinal tract. Rapid gastrointestinal 
transit can prevent the absorption of complete drug in the 
absorption zone and reduce the efficacy of the administered 
dose since the majority of drugs are absorbed in stomach or 
the upper part of small intestine[1,2]. 
   To overcome the above discussed issues, many types of 
oral controlled drug delivery systems having prolonged 
gastric residence times have been reported such as: floating 
drug dosage systems (FDDS)[3-7], swelling or expanding 
system[8], mucoadhesive systems[9,10], modified-shape 
systems[11], high-density systems and other delayed gastric 
emptying devices[12].
   FDDS have lower density than gastric fluids and thus remain 
buoyant in the stomach fluid without affecting the gastric 
emptying for a prolonged period of time. While the system is 
floating in the gastric fluid, the drug is released slowly from 
the system at a desired rate. Materials used for FDDS include 
carbon dioxide gas-forming agents (carbonate or bicarbonate 
compounds)[8,13], highly swellable hydrocolloids and light 
mineral oils[14,15]. Multiple unit systems and floating systems 
prepared by solvent evaporation methods have also been 
developed[12,16-20].
   However, it has been shown that products based on a 
multiple unit system comprising many small units have 
ARTICLE INFO                          ABSTRACT
Objective: To develop and characterize multiple-unit-type oral floating microsphere of 
famotidine to prolong gastric residence time and to target stomach ulcer. 
Methods: The floating microspheres were prepared by modified solvent evaporation method. 
Eudragit S-100 was used as polymer. Microspheres were characterized for the micromeritic 
properties, floating behavior, entrapment efficiency and scanning electron microscopy. The in-
vitro release studies and floating behavior were studied in simulated gastric fluid at pH 1.2. 
Different drug release kinetics models were also applied for all the batches. Selected formulations 
were also subjected for X-ray radiographic study.
Results: Floating microspheres were successfully prepared by modified solvent evaporation 
technique. Microspheres showed passable flow properties. The maximum yield of microspheres 
was up to (95.11依0.35)%. On the basis of optical microscopy particle size range was found to 
be ranging from (52.18依182.00) to (91.64依5.16) µm. Scanning electron microscopy showed their 
spherical size, perforated smooth surface and a cavity inside microspheres. Microspheres were 
capable to float up to 20 h in simulated gastric fluid. X-ray radiographic studies also proved its 
better retention in the stomach. 
Conclusions: On the basis of the results, such dosage forms may be a good candidate for stomach 
targeting and may be dispensed in hard gelatin capsules. 
Article history:
Received 20 Feb 2014
Received in revised form 26 Mar 2014
Accepted 15 May 2014
Available online 28 Jun 2014
Keywords:
Floating microspheres
Famotidine
Floating drug delivery
Stomach targeting
 Contents lists available at ScienceDirect
Rishikesh Gupta et al./Asian Pac J Trop Biomed 2014; 4(9): 729-735730
advantages over single-unit preparations such as matrix 
tablets[21]. The gastric emptying of multiple unit dosage 
forms occur gradually, in a more consistent manner, with 
less individual variation[2,22]. Multiple unit dosage forms 
also have the potential to distribute widely over a large area 
in the stomach and small intestine, thus yielding a more 
predictable drug release by suppressing the effect of many 
variables in the gastrointestinal environment. As multiple 
unit dosage forms consist of many small units, less risk of 
dosage dumping is expected[23].
   Famotidine, a competitive histamine H2-receptor antagonist 
is used to treat gastrointestinal disorders such as gastric 
or duodenal ulcer, gastroesophageal reflux disease, and 
pathological hypersecretory conditions. Famotidine inhibits 
many of the isoenzymes of the hepatic CYP450 enzyme system. 
Other actions of famotidine include an increase in gastric 
bacterial flora such as nitrate-reducing organisms[24].
   Famotidine is widely used as the treatment of peptic ulcer 
disease and gastroesophageal reflux disease. Famotidine 
binds competitively to H2-receptors located on the 
basolateral membrane of the parietal cell, blocking histamine 
affects. This competitive inhibition results in reduced basal 
and nocturnal gastric acid secretion and a reduction in 
gastric volume, acidity, and amount of gastric acid released 
in response to stimuli including food, caffeine, insulin, 
betazole and pentagastrin[25].
   Floating microspheres are one of the multiparticulate 
delivery system and are prepared to obtain prolonged or 
controlled drug delivery to improve bioavailability and to 
target drug to specific sites. Microspheres can also offer 
advantages like limiting fluctuation within therapeutic range, 
reducing site effects, decreasing dosing frequency and 
improving patient compliance[26].
   In the present study, the multiple-unit-type oral floating 
microspheres bearing famotidine were developed by modified 
solvent evaporation technique. Eudragit S-100 was used as 
polymer.
   The high surface tension of stirring phase causes the 
solidification and aggregation of polymer on the surface when 
the polymeric solution is poured from upside. To minimize 
the contact of polymer solution with interface, a new method 
of introducing the polymer solution into stirring phase was 
adopted as established by Lee et al[27].
 
2. Materials and methods
   Famotidine was obtained as a gift sample from Cadila 
Pharmaceutical Ltd., Mumbai (Maharastra). Eudragit S100 
(Rohm Pharma GmbH, Germany) was used as polymers. All 
other chemicals and reagents were of analytical grade and 
were used without further purification.
2.1. Preparation of floating microspheres
   Floating microspheres were prepared by the method 
reported by Kawashima et al. with slight modifications[19]. 
Ten formulations of floating microspheres were developed. 
Different ratios of famotidine and Eudragit S-100 were mixed 
in a mixture of dichloromethane (DCM) and ethanol (Table 
1). The resulting suspension was added slowly into stirring 
to 0.25% w/v 400 mL solution of polyvinyl alcohol (PVA) at 
room temperature from the bottom side as shown in Figure 
1[27]. The stirring was continued for 2 h by mechanical stirrer 
equipped with four blade propellers in order to evaporate 
the solvent. After evaporation of solvent, microspheres were 
collected by filtration and washed repeatedly with water. The 
collected microspheres were dried at room temperature and 
stored in a desiccator.
Table 1
Batch specifications for floating microspheres.
Code Drug: polymer (mg) Speed Solvent ratio  (DCM: ethanol, mL)
FS-1 1:1   900 1:1
FS-2 1:2   900 1:1
FS-3 1:3   900 1:1
FS-4 1:4   900 1:1
FS-5 1:5   900 1:1
FS-6 1:3 1 000 1:1
FS-7 1:3 1 200 1:1
FS-8 1:3 1 300 1:1
FS-9 1:3   900 1:3
FS-10 1:3   900 3:1
Figure 1. Method of injection of volatile phase into PVA solution.
2.2. Characterization of floating microspheres
2.2.1. Morphology
   The morphology of microspheres was studied by scanning 
electron microscopy (SEM). The samples for SEM were prepared 
by sprinkling the microspheres on a both side adhesive tape 
stuck to a stub. Gold palladium coating on the prepared stub 
was done by using sputter coater (POLARON model SC-76430). 
The thickness of coating was 200 Å. The coated stubs were 
randomly scanned under electron microscope (LEO-430, UK). 
The photomicrograph of prepared microspheres are presented 
in Figure 2.
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2.2.2. Particle size analysis
   The size of microspheres was determined by using an 
optical microscope (Magnus MLX-DX, Olympus, India) fitted 
with an ocular micrometer and a stage micrometer. The mean 
particle size was calculated by measuring 200-300 particles.
2.2.3. Micromeritic properties
   The prepared microspheres were characterized for their 
micromeritic properties such as true density, tapped density 
and % compressibility index. The tapping method was used to 
calculate tapped densities and % compressibility index using 
following equations[28]:
 
Tapped density =
Mass of microspheres
Volume of microspheres after tapping
Compressibility index (%) =(1-V/VO)×100
   Where V and Vo are the volumes of the samples after and 
before the standard tapping respectively.
   True density of floating microspheres was determined by 
immersing the microparticles in 0.02% Tween 80 solution 
for three days in a metal mesh basket. The microparticles 
that were sunk after the process were used for density 
measurement as carried out by the displacement method[29].
2.2.4. Angle of repose
   Flow characteristic such as angle of repose (θ) of the 
microspheres, which measures the resistance to particle 
flow, was determined by fixed funnel method using following 
equation[28]:
Tan θ=
h
  r
   Where, h is the height of pile, r is the radius of the base of 
pile on the graph paper.
2.2.5. Yield of microspheres
   The prepared microspheres were collected and weighed. 
The actual weight of obtained microspheres divided by the 
total amount of all drug and polymer solid material that was 
used for the preparation of the microspheres[30]:
Yield (%) = ×100   Actual weight of the product
Total weight of the excipients and drug
2.2.6. Incorporation efficiency
   To determine the incorporation efficiency 50 mg 
microspheres were taken and dissolved in 25 mL of methanol. 
The solution was filtered to separate shell fragments. The 
estimation of drug was carried out at the λmax of 264 nm 
by using a UV double-beam spectrophotometer (Shimadzu 
UV-1 800 series). The incorporation efficiency was calculated 
using following equation[30]:
Incorporation efficiency= ×100   
Calculated drug content
Theoretical drug content
2.2.7. In-vitro floating ability
   Floating microspheres (50 mg) were placed in 100 mL 
beaker. A total of 10 mL of 0.1 mol/L HCl containing 0.02% 
Tween 20 was added to that. The beaker was shaken 
horizontally in a water bath at (37.0依0.1) °C. Floated particles 
were collected after 20 h and dried in a desiccator till 
constant weight. This process was applied to all the batches. 
Floating microspheres are shown in Figure 3. The percentage 
of floating microspheres was calculated using following 
equation[30]:
Floating ability (%) = ×100   
Weight of floating microspheres
Initial weight of microspheres
Figure 3. Floating microspheres.
 
Floating microspheres
Figure 2. Scanning electron micrograph of floating microsphere.     
A: Photo micrograph showing population of batch FS-3; B: Photo micrograph showing a floating cavity and porous surface in microsphere of batch FS-5.
Photo No=197 Photo No=460838 µm 10 µm Mag= 432伊    BSIPMag= 500伊 BSIP
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2.3. In-vitro drug release
   In-vitro drug release studies were performed in 
0.1 mol/L HCl (pH 1.2) for floating microspheres. The drug 
release rate of the floating microspheres was determined 
in 900 mL 0.1 mol/L HCl at 100 r/min by using USP XXIII 
dissolution apparatus (paddle type). A weighed amount 
of floating microspheres equivalent to 50 mg drug was 
placed in a non-reacting muslin cloth having a smaller 
mesh size than the microspheres. The mesh was tied with 
a nylon thread to avoid the escape of any microspheres 
and a glass bead was placed in the mesh to induce 
sinking of microspheres in the dissolution medium[31]. 
The temperature of dissolution medium was maintained at 
(37.0依0.5) °C.
   At specified time intervals, 5 mL aliquots were 
withdrawn, filtered, diluted with the same medium and 
assayed at 264 nm for famotidine using a UV double-beam 
spectrophotometer (Shimadzu UV-1 700 series). Samples 
withdrawn were replaced with equal volume of the same 
dissolution medium. All the experiments as specified 
above were conducted in triplicate.
2.4. Kinetics of drug release 
   The zero-order rate (equation 1) describes systems where 
drug release is independent of its concentration and this 
is applicable to the dosage forms like transdermal system, 
coated forms, osmotic system as well as matrix tablets with 
low soluble drugs. The first-order equation (equation 2) 
describes systems in which the release is dependent on its 
concentration (generally seen for water-soluble drugs in 
porous matrix). The Higuchi model describes the release of 
the drug from an insoluble matrix to be linearly related to 
the square root of time and is based on Fickian diffusion 
(equation 3). The Hixson-Crowell cube root law (equation 
4) describes the release of drug from systems where it 
depends on the change in surface area and diameter of the 
particles or tablets with time and mainly applies in the 
case of systems that dissolute or erode over time. In order 
to authenticate the release model, dissolution data can 
further be analyzed by Peppas and Korsmeyer equation 
(equation 5). 
   Qt=kn t                                (equation 1)
   ln Qt=ln Qo-k1 t                   (equation 2)
   Qt=kHC t
1/2                            (equation 3)
   Qo
1/3-Q1/3=kHC t                     (equation 4)
   Mt/M∞=k t
n                          (equation 5)
   Where Qt is the amount of drug released at time t; Q0 is 
the initial amount of the drug in the formulation; k0, k1, kH, 
and kHC are release rate constants for zero-order, first-
order, Higuchi model and Hixson-Crowell rate equations. 
In equation 5, Mt is the amount of drug released at time t, 
and M∞ is the amount of drug released at time ∞; k is the 
kinetic constant, and n is the diffusion coefficient[32].
   The release data of various formulations were fitted 
in various models to ascertain the mechanism of drug 
release.
2.5. Preparation of dosage form for radiographic study
   The optimized formulations which showed good in-
vitro buoyancy and sustained release behavior were finally 
selected for radiography study. The drug in all selected 
formulations was replaced with the same amount of barium 
sulphate while all other ingredients were kept constant. These 
formulations were analyzed for their physical properties. The 
analysis confirmed that the developed dosage forms were 
similar to those containing drug.
2.5.1. Radiographic studies 
   The experimental protocol to carry out in-vivo radiographic 
studies were reviewed and approved by the Institutional 
Animals Ethical Committee of Institute of Pharmacy, 
Bundelkhand University, Jhansi, India (Registration No. BU/
Pharm/IAEC/10/031). The in-vivo radiographic studies were 
conducted in young and healthy male albino rabbits weighing 
2.0 kg to 2.2 kg. The animals were kept under standard 
laboratory conditions [temperature (25依2) °C]. Rabbits were 
kept for one week in animal house to acclimatize them and 
were fed a fixed standard diet. The 4 healthy male albino 
rabbits were used to monitor the in-vivo transit behavior of 
the prepared floating microspheres. None of the animal had 
symptoms or past history of gastro-intestinal disease. In order 
to standardize the conditions of gastrointestinal motility, the 
animals were fasted for 12 h prior to the commencement of 
each experiment. In each experiment, the first radiographic 
image of the animal subjects was taken to ensure the absence 
of radio-opaque material in the gastrointestinal tract. One of 
each dosage form (capsule containing microspheres) prepared 
for radiography was orally administered to rabbits with 
sufficient amount of water. During the study the rabbits were 
not allowed to eat, but water available with ad libitum[33,34].
   For radiographic imaging, the legs of the rabbit were tied 
over a piece of plywood (20 inch×20 inch), and location of 
the formulation in the stomach was monitored by keeping 
the subjects in front of X-ray machine (Allengers, Bharat 
Electricals, India, model No. E-080743). The distance 
between the source of X-rays and the object was kept same 
during the imaging process. Gastric radiography was done 
at the intervals of 0 h, 1 h, 3 h, 5 h and 6 h. In between the 
radiographic imaging, the animals were freed and allowed to 
move and carry out normal activities but were not allowed to 
take any food.
 
3. Results 
   The formulations of famotidine loaded floating microspheres 
were developed by modified solvent evaporation method. In 
this method, the drug-polymeric suspension was introduced 
into stirring 0.25% w/v solution of PVA from bottom side to 
reduce the aggregation of polymer on the top of PVA. This 
technique produced more spherical microspheres and good 
yield of product could be achieved.
   The formulation mechanism of polymeric floating 
microspheres is well documented in the literature (Figure 4). 
The polymer and drug were dissolved in solvent mixture such 
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as dichloromethane and ethanol. The polymeric mixture at 
different ratio were dissolved in a volatile solvent (ethanol, 
dichloromethane combined) as given in Table 1. This 
polymeric drug solution was poured in 0.25% w/v solution of 
PVA. Thus, an O/W emulsion was formed. The ethanol present 
in oil droplet diffuse, to water thus polymer and drug mixture 
solidified on dichloromethane droplet. Now the temperature 
was raised up to 45 °C-50 °C. After evaporation of solvent, 
microspheres were collected by filtration, washed with water, 
and dried at room temperature. As a result, hollow cavity 
within microspheres was formed.
Figure 4. Mechanism of formation of floating microspheres.
ETN: Erythrityl tetranitrate; DCM: Methylene chloride.
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   SEM photo micrograph confirmed that prepared 
microspheres were spherical with smooth perforated surface 
(Figure 2). The formation of perforation may be attributed 
to evaporation of alcohol form embryonic microspheres. 
The prepared microspheres were found to be spherical 
in shape with smooth perforated surface as indicated by 
photomicrographs. Floating cavities could also be observed 
on some micrographs.
   The mean particle size of the floating microspheres was 
found to be ranging from (52.18依1.82) µm to (91.64依5.16) µm. 
It was observed that, on increasing the polymer amount, 
the average particle size increased. This may be due to 
diminished shearing efficiency at higher concentration of 
the polymer (higher viscosity). It was also observed that on 
increasing the volume of DCM, average particle size was found 
to be increased (Table 2).
Table 2
Micromeritic properties of floating microspheres.
Formulation 
code
Mean particle 
sizea  (µm)
Bulk densityb  
(g/cm3)
Tapped densityb
(g/cm3)
Compressibility 
indexb
Angle of 
reposeb
FS-1 52.18依182 0.185依0.070 0.165依0.120 25.07依1.23 32.56依0.85
FS-2 60.32依3.01 0.166依0.030 0.154依0.340 28.31依4.65 20.89依0.38
FS-3 77.75依6.84 0.160依0.090 0.145依0.070 34.21依4.01 21.16依1.10
FS-4 82.24依7.94 0.151依0.080 0.131依0.090 41.01依2.25 23.04依0.42
FS-5 91.64依5.16 0.145依0.040 0.124依0.060 49.31依0.36 24.01依0.94
FS-6 78.02依2.67 0.155依0.060 0.149依0.130 35.94依1.45 25.00依0.71
FS-7 71.31依0.89 0.169依0.040 0.175依0.640 29.02依2.64 29.74依1.48
FS-8 63.94依4.23 0.188依0.040 0.191依0.010 21.14依6.02 30.07依0.58
FS-9 56.30依0.78 0.195依0.300 0.199依0.070 19.84依0.08 19.31依0.89
FS-10 85.18依6.54 0.175依0.020 0.188依0.610 32.01依1.34 32.70依2.95
a: Mean依SD, n=200-300; b: Mean依SD, n=3.
   The measured tapped density was found to be in the range 
of (0.124依0.06) g/cm3to (0.199依0.070) g/cm3. Compressibility 
index ranged from (19.84依0.08) to (49.31依0.36) (Table 2).
   The angle of repose was found to be in the range of (19.31
依0.89) to (32.56依0.85). All the batches showed good flow 
properties except bathes FS-1 and FS-8 which exhibited 
higher angle of repose (Table 2).
   The yield was found to be ranging from (69.74依1.35)% to 
(95.11依0.35)%. The drug entrapment/incorporation efficiency 
of microspheres was found to be satisfactory (55.75依2.94)% to 
(75.35依1.96)% (Table 3).
Table 3
Various formulation parameters of floating microspheres.
Formulation code  Yielda (%) Incorporation efficiency
a
Buoyancy %
a
FS-1 69.74依1.35 55.75依2.94 68.84依2.15
FS-2 78.94依2.65 57.35依1.75 73.16依1.76.
FS-3 81.75依0.45 60.70依2.94 86.46依1.64
FS-4 88.94依1.75 62.94依2.67 88.64依2.99
FS-5 95.11依0.35 65.74依2.94 95.81依2.46
FS-6 78.45依2.31 68.94依1.75 83.46依2.81
FS-7 79.44依2.03 70.88依3.16 75.11依2.41
FS-8 81.91依1.66 75.35依1.96 79.78依2.38
FS-9 70.46依1.74 57.68依1.09 61.64依2.67
FS-10 73.45依1.81 59.64依2.97 96.15依2.46
a: Mean依SD, n=3.
   All floating microspheres showed good floating ability/ 
buoyancy (61.64依2.67)% to (95.81依2.46)% up to 20 h. This could 
be attributed to insolubility of used polymers in the gastric 
fluid. It was observed that the floating ability increased with 
increasing average particle size (Table 3).
   It was also observed that the formulation prepared with 
higher volume of DCM (batch FS-10) showed better floating 
ability as compared to other batches. The reason behind this 
may be the formation of larger air core, which made them 
lesser dense than that of gastric fluid.
   The release of famotidine from the developed floating 
microspheres was studied in 0.1 mol/L HCl (pH 1.2) up to 
20 h. Since the acrylic polymers are insoluble in acidic 
medium, the microspheres retained their integrity during in-
vitro dissolution studies. The cumulative % drug release for 
microspheres was found to be between 85-98% (Figures 5- 7).
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Figure 5. Effect of polymer ratio on release profile of drug in 0.1 mol/L HCl.
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Figure 6. Effect of stirring ratio on release profile of drug in 0.1 mol/L HCl.
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Figure 8. Radiographic images showing the presence of BaSO4 loaded 
floating microspheres in the stomach at different time intervals. Images were 
taken after a: 0 h, b: 1 h, c: 3 h, d: 5 h.
A
B
C
D
  
   The release profile data of all the developed formulations 
were fitted in kinetic model using PCP Disso software. The 
best model was selected on the basis of goodness of fit the 
values of residual sum of squares (RSS).
   The drug release of batches FS-1, FS-2 and FS-9 showed 
first order drug release and remaining all the batches showed 
Higuchi (Matrix) model (Table 4). 
   The hard gelatin capsule containing BaSO4 loaded floating 
microspheres were clearly visible in stomach after oral 
administration of dosage form. In radiographic image taken 
after 1 hour, all microspheres were found to be scattered in 
stomach. Dense images of microspheres were seen at initial 
hours, but as time passed on the images of microspheres 
became lighter. It may be because of distribution and 
scattering of microspheres within gastrointestinal region. The 
radiographic images indicted that these floating microspheres 
retained successfully in the stomach up-to 6 hours (Figure 8).
4. Discussion
   Novel floating microspheres were successfully prepared 
by solvent evaporation method with modified technique of 
administration of polymeric solution from bottom side, for 
prolonged as well as stomach specific action of famotidine. 
Due to their low densities, this multi particulate drug delivery 
system showed good floating ability.
   It was noted, on increasing the polymer ratio the cumulative 
% drug release decreased gradually. It may be because of 
increased partitioning of drug in polymer (Eudragit S-100). It 
was also observed that the release of famotidine decreased 
significantly (P<0.05) on increasing the amount of polymers.
   Further, a significant increase was found in drug release on 
increasing the stirring rate. It may be because of increased 
surface area of microspheres due to reduced size. 
   On increasing the volume of ethanol in solvent phase 
the release was found to be increased. On the other hand, 
when the volume of DCM was increased, the release of drug 
was found to be decreased. The reason behind this may be 
the size of microspheres which increases on increasing the 
volume of DCM. 
   From in-vitro drug release studies, it can be concluded that 
by changing the ratio of polymer and solvent, drug release 
can be controlled. These floating microspheres containing 
famotidine could be dispensed by filling them in the empty 
capsule shell.
   In-vivo radiographic images were also helpful to locate 
the position of floating micro spheres in gastrointestinal 
tract. And this study also confirmed that the prepared 
maicrospheres were able to retain in stomach for prolonged 
Table 4
Drug release kinetics for different formulations.
Formulation code Zero-order First order Higuchi Hixon-Crowell Peppas and Korsmeyer Best fit model
R RSS k0 R RSS k1 R RSS kH R RSS kHC R RSS k n
FS-1 0.0071 11334 6.7027 0.9740  849 -0.221 0.895 2252 26.44 0.869 3251 -0.044 0.911 1342 33.74 0.410 FO
FS-2 0.3195 10186 6.6340 0.9802  666 -0.213 0.915 1833 26.06 0.894 2778 -0.043 0.923 1222 31.65 0.431 FO
FS-3 0.5710   6305 6.0150 0.9530  928 -0.151 0.959 7460 23.35 0.921 2219 -0.034 0.958   412 28.16 0.430 M
FS-4 0.5170   6190 5.7000 0.9320 1543 -0.118 0.949 8250 22.22 0.849 2685 -0.030 0.942   561 25.90 0.447 M
FS-5 0.6290   4764 5.3800 0.9400 1272 -0.103 0.967 5100 20.85 0.873 2130 -0.0270 0.950   466 22.30 0.482 M
FS-6 0.6530   5245 5.8500 0.9610  799 -0.139 0.973 4830 22.63 0.935 1840 -0.0330 0.966   304 25.97 0.450 M
FS-7 0.5940   6165 6.0500 0.9530  765 -0.158 0.964 6690 23.48 0.933 2025 -0.0350 0.962   366 28.10 0.433 M
FS-8 0.5090   7277 6.2500 0.9610  736 -0.178 0.952 9070 24.35 0.932 2253 -0.0380 0.961   394 30.87 0.409 M
FS-9 0.5340   6990 6.1900 0.9630  800 -0.168 0.955 8610 24.09 0.929 2246 -0.0370 0.958   435 29.68 0.421 FO
FS-10 0.6090   5721 5.8600 0.9590 1000 -0.137 0.964 6430 22.74 0.918 2141 -0.0328 0.955   427 26.26 0.448 M
RSS: Residual sum of squares; K: Release constant; n: Diffusion coefficient; H: Higuchi (Matrix); HC: Hixson-Crowell; FO: First order; M: Matrix.
Rishikesh Gupta et al./Asian Pac J Trop Biomed 2014; 4(9): 729-735 735
release of famotidine. 
Conflict of interest statement
   We declare that we have no conflict of interest.
Acknowledgements
   We are thankful to Cadila Pharmaceutical Ltd., Gujarat, for 
providing gift sample of famotidine and Degussa India Pvt. 
Ltd. for providing Eudragit S-100 polymer as a gift sample. 
We also wish to thank to the Director, Birbal Sahni Institute of 
Palaeobotany, Lucknow, India, for providing us SEM facility.
References
[1]    Kaushik K, Chaurasia D, Chaurasia H, Mishra SK, Bhardwaj P. 
Development and characterization of floating alginate beads for 
gastroretentive drug delivery system. Acta Pharma Sci 2011; 53(4): 
551-562.
[2]    Tadros MI. Controlled-release effervescent floating matrix tablets 
of ciprofloxacin hydrochloride: development, optimization and in 
vitro-in vivo evaluation in healthy human volunteers. Eur J Pharm 
Biopharm 2010; 74(2): 332-339.
[3]    Baumgartner S, Kristl J, Vrecer F, Vodopivec P, Zorko B. Optimisation 
of floating matrix tablets and evaluation of their gastric residence 
time. Int J Pharm 2000; 195(1-2): 125-135.
[4]    Bulgarelli E, Forni F, Bernabei MT. Effect of matrix composition and 
process conditions on casein-gelatin beads floating properties. Int J 
Pharm 2000; 198(2): 157-165.
[5]    Davoudi ET, Noordin MI, Kadivar A, Kamalidehghan B, Farjam AS, 
Javar HA. Preparation and characterization of a gastric floating dosage 
form of capecitabine. Biomed Res Int 2013; doi: 10.1155/2013/495319.
[6]    Singh BN, Kim KH. Floating drug delivery systems: an approach to 
oral controlled drug delivery via gastric retention. J Control Release 
2000; 63(3): 235-259.
[7]    Garg R, Gupta G. Progress in controlled gastroretentive delivery 
systems. Trop J Pharm Res 2008; 7(3): 1055-1066. 
[8]    Chen J, Park K. Synthesis of fast-swelling, superporous sucrose 
hydrogels. Carbohyd Polym 2000; 41(3): 259-268.
[9]    Shaikh R, Singh TRR, Garland MJ, Woolfson AD, Donnelly RF. 
Mucoadhesive drug delivery systems. J Pharm Bioallied Sci 2011; 
3(1): 89-100.
[10]  Boddupalli BM, Mohammed ZNK, Nath RA, Banji D. Mucoadhesive 
drug delivery system: an overview. J Adv Pharm Technol Res 2010; 
1(4): 381-387.
[11]  Kedzierewicz F, Thouvenot P, Lemut J, Etienne A, Hoffman M, 
Maincent P. Evaluation of peroral silicone dosage forms in hymans by 
gamma-scintigraphy. J Control Release 1999; 58(2): 195-205.
[12]  Rouge N, Allémann E, Gex-Fabry M, Balant L, Cole ET, Buri P, et 
al. Comparative pharmacokinetic study of a floating multiple-unit 
capsule, a high density multiple-unit capsule and an immediate-
release tablet containing 25 mg atenolol. Pharm Acta Helv 1998; 73(2): 
81-87. 
[13]  Prajapati PH, Nakum VV, Patel CN. Formulation and evaluation of 
floating matrix tablet of stavudine. Int J Pharm Investig 2012; 2(2): 83-
89.
[14]  Chaturvedi K, Umadevi S, Vaghani S. Floating matrix dosage form 
for propranolol hydrochloride based on gas formation technique: 
development and in vitro evaluation. Sci Pharm 2010; 78(4): 927-939. 
[15]  Murata Y, Sasaki N, Miyamoto E, Kawashima S. Use of floating 
alginate gel beads for stomach-specific drug delivery. Eur J Pharm 
Biopharm 2000; 50(2): 221-226.
[16]  Jagtap YM, Bhujbal RK, Ranade AN, Ranpise NS. Effect of various 
polymers concentrations on physicochemical properties of floating 
microspheres. Indian J Pharm Sci 2012; 74(6): 512-520.
[17]  Jain AK, Jain CP, Tanwar YS, Naruka PS. Formulation, 
characterization and in vitro evaluation of floating microspheres of 
famotidine as a gastro retentive dosage form. Asian J Pharm 2009; 3(3): 
222-226.
[18]  El-Kamel AH, Sokar MS, Al Gamal SS, Naggar VF. Preparation and 
evaluation of ketoprofen floating oral delivery system. Int J Pharm 
2001; 220(1-2): 13-21.
[19]  El-Kamel AH, Sokar MS, Al Gamal SS, Naggar VF. Development of 
floating microspheres to improve oral bioavailability of cefpodoxime 
proxetil. Int J Pharma 2001; 220: 13-21.
[20]  Wakde PH, Kasliwal RH, Mane SB. Design and fabrication of 
gastroretentive bilayer floating tablet of propronolol HCl using natural 
polymer. Int J Pharm Sci Res 2013; 4(12): 4715-4728. 
[21]  Pandya N, Pandya M, Bhaskar VH. Preparation and in vitro 
characterization of porous carrier-based glipizide floating 
microspheres for gastric delivery. J Young Pharm 2011; 3(2): 97-104.
[22]  Jagdale SC, Agavekar AJ, Pandya SV, Kuchekar BS, Chabukswar AR. 
Formulation and evaluation of gastroretentive drug delivery system 
of propranolol hydrochloride. AAPS PharmSciTech 2009; 10(3): 1071-
1079.
[23]  Hussain MN, Masum MAA, Akhter S, Sharmin F, Reza MS. 
Formulation and evaluation of gastro retentive floating tablets of 
simvastatin using hydrophilic rate retardant. Bangladesh Pharm J 
2012; 15(2): 119-126. 
[24]  Al-Omar MA, Al-Mohizea AM. Famotidine, analytical profile. In: 
Brittain HG, editor. Profiles of drug substances, excipients and related 
methodology. Burlington: Academic Press; 2009, p. 115-151.
[25]  Muzib YI, Ch Rekha. Development and evaluation of mineral oil 
entrapped emulsion gel beads of famotidine. Int J Pharmacol 
Technol 2011; 3(2): 83-90.
[26]  Haznedar S, Dortunc B. Preparation and in vitro evaluation of eudragit 
microspheres containing acetazolamide. Int J Pharm 2004; 269(1): 
131-140.
[27]  Lee JH, Park TG, Choi HK. Development of oral drug delivery system 
using floating microspheres. J Microencapsul 1999; 16(6): 715-729.
[28]  Bhardwaj P, Singh R, Swarup A. Development and in-vitro evaluation 
of floating microspheres of 5-fluorouracil. Int J Pharm Sci Res 2012; 
3(3): 934-941. 
[29]  Soppimath KS, Kulkarni AR, Aminabhavi TM. Development of 
hollow microspheres as floating controlled-release systems for 
cardiovascular drugs: preparation and release characteristics. Drug 
Dev Ind Pharm 2001; 27(6): 507-515.
[30]  Patel A, Ray S, Thakur RS. In-vitro evaluation and optimization 
of controlled release floating drug delivery system of metformin 
hydrochloride. DARU 2006; 14(2): 57-64.
[31]  Chaurasia D, Kaushik K, Bhardwaj P, Chaurasia H, Jain SK, Shobhna 
S. Development and in-vitro characterization of floating microsphere 
bearing tramodol HCl. Acta Pol Pharm-Drug Res 2011; 68(5): 795-801.
[32]  Bhardwaj P, Chaurasia D, Chaurasia H, Gupta R, Prajapati 
SK. Development and in-vitro evaluation of site-specific 
floating miltiparticulate drug delivery system for stomach. Int J 
Pharmagenesis 2011; 2(1): 5-13. 
[33]  Jagdale SC, Bari NA, Kuchekar BS, Chabukswar AR. Optimization 
studies on compression coated floating-pulsatile drug delivery of 
bisoprolol. Biomed Res Int 2013; doi: 10.1155/2013/801769.
[34]  Shah SS, Pandya SJ, Waghulade MK. Development and investigation 
of gastro retentive dosage form of weakly basic drug. Asian J Pharm 
2010; 4(1): 11-16.
